JIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares (ZJYL)
$3.87▼ −21.18%
Close Nov 12, 2026 · split-adjusted
Nov 12, 2026$3.87▼ 96.36% in range
Nov 12, 2025Low $1.81 · High $944.00Nov 12, 2026
What changed · written from our data
As of Nov 12, 2026
JIN MEDICAL INTERNATIONAL closed at $3.87 on Nov 12, down 21.18%, 99.6% below its 52-week closing high. Volume of 153.7K shares was 0.65× its 20-day average (below normal).
Split-adjusted performance: +91.6% over one month, +57.3% over six months.
Short interest was 7.5K shares at the Oct 30 settlement, down 84.7% from the prior report (0.0% of float, 1.0 days to cover).
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility.
What is ZJYL's market cap?
$285.08M, based on the Nov 12 close of $3.87.
Does JIN MEDICAL INTERNATIONAL pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ZJYL is sold short?
7.5K shares, 0.0% of float, as of Oct 30, 2026.
About JIN MEDICAL INTERNATIONAL
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
